Sugi Predict

Sugi Predict / Compounds / SCHEMBL914722

SCHEMBL914722

SCHEMBL914722

O=C(O)c1cc2c(OCc3ccccc3)cccc2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRD5A2 P31213 4/20 1.00
▸ SRD5A1 P18405 1/20 0.58
▸ KDM4E B2RXH2 4/20 0.56
▸ HSD17B10 Q99714 4/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ HPGD P15428 3/20 0.56
▸ CYP1A2 P05177 2/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ GAA P10253 2/20 0.54
▸ GRIN2D O15399 1/20 0.54
▸ GRIN3B O60391 1/20 0.54
▸ GLA P06280 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ AHR P35869 1/20 0.54
▸ CHRNA7 P36544 1/20 0.54
▸ GRIN1 Q05586 1/20 0.54
▸ GRIN2A Q12879 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30397127 1.00 SRD5A2 (1.00) SRD5A2SRD5A1KDM4EHSD17B10ALDH1A1
SCHEMBL9134860 0.89 SRD5A2 (0.81) SRD5A2SRD5A1KDM4EHSD17B10ALDH1A1
SCHEMBL6595625 0.87 SRD5A2 (0.77) SRD5A2SRD5A1KDM4EHSD17B10ALDH1A1
SCHEMBL2007875 0.86 SRD5A2 (0.76) SRD5A2SRD5A1KDM4EHSD17B10ALDH1A1
SCHEMBL2007950 0.85 SRD5A2 (0.74) SRD5A2KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL914679 0.85 SRD5A2 (0.73) SRD5A2SRD5A1KDM4EHSD17B10ALDH1A1
SCHEMBL700753 0.85 SRD5A2 (0.73) SRD5A2SRD5A1KDM4EHSD17B10ALDH1A1
SCHEMBL2005930 0.84 SRD5A2 (0.73) SRD5A2SRD5A1KDM4EHSD17B10ALDH1A1
SCHEMBL10002809 0.84 SRD5A2 (0.72) SRD5A2SRD5A1KDM4EHSD17B10ALDH1A1
SCHEMBL8177919 0.84 SRD5A2 (0.72) SRD5A2SRD5A1KDM4EHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103923765-A Detergent Composition For Process Of Manufacturing Semiconductors And Displays COWON INNOTECH INC 2014-07-16 — — CN claimed
US-8183366-B2 Chemokine receptor antagonists NOVARTIS AG (CH) 2012-05-22 — — US claimed
CN-102391251-A Chemokine receptor antagonists NOVARTIS AG 2012-03-28 — — CN claimed
EP-1720859-B1 CHEMOKINE RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2009-12-23 — — EP claimed
WO-2009063495-A2 SUBSTITUTED INDOLE AND ITS DERIVATIVES AS CANNABINOID MODULATORS CADILA HEALTHCARE LIMITED (IN) 2009-05-22 — — WO claimed
US-20070155721-A1 Chemokine receptor antagonists NOVARTIS AG (CH) 2007-07-05 — — US claimed
CN-1946713-A Chemokine receptor antagonists NOVARTIS AG (CH) 2007-04-11 — — CN claimed
EP-1720859-A2 CHEMOKINE RECEPTOR ANTAGONISTS Novartis AG (CH) 2006-11-15 — — EP claimed
WO-2005077932-A2 CHEMOKINE RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2005-08-25 — — WO claimed
US-11952365-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-09 — — US disclosed
US-20230159502-A1 INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 — — US disclosed
CN-116096714-A Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections 安力高医药股份有限公司 2023-05-09 — — CN disclosed
CN-115916748-A Indole derivatives as alpha-1 antitrypsin modulators for the treatment of alpha-1 antitrypsin deficiency (AATD) 弗特克斯药品有限公司 2023-04-04 — — CN disclosed
EP-4132908-A1 INDOLE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) Vertex Pharmaceuticals Incorporated (US) 2023-02-15 — — EP disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 — — EP disclosed
EP-0622356-A1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1994-11-02 — — EP disclosed
US-5229412-A Administering carrier with anxiolytic derivatives of N-(3-/4-indolyloxy/-2-hydroxypropyl)-1,8-diamino-p-menthane THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1993-07-20 — — US disclosed
WO-1992018089-A2 USE OF STEROIDAL AND NON-STEROIDAL AMINES TO SENSITIZE MULTIDRUG-RESISTANT CELLS THE UPJOHN COMPANY (US) 1992-10-29 — — WO disclosed
US-5137910-A Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders C.D. SEARLE & CO. (US) 1992-08-11 — — US disclosed
EP-0338877-A1 Selective binding compounds for 5-hydroxytryptamine 1-A-receptors and pharmaceutical compositions containing them THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1989-10-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159502-A1 INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 SRD5A2 1153/4885SRD5A1 469/4885KDM4E 4550/4885
US-11952365-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 SRD5A2 1506/4885SRD5A1 1057/4885KDM4E 3205/4885
US-20070155721-A1 Chemokine receptor antagonists ACKR3, CXCR2, CXCR4 SRD5A2 869/4885SRD5A1 821/4885KDM4E 4275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.